Nationwide Children's Research News
Viewing: 51-60 of 380 | All
Jan 18, 2023
Genomic Medicine, Physician Dedication Give Family Answers About Teen’s Rare Disease
Through whole exome sequencing performed in 2020 at the Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children’s, one family was finally able to put a real name to their adolescent's rare disease.
Nov 03, 2022
“The Ripple Effect” New Study Illustrates Vast Influence Children’s Mental Health Concerns have on Workforce Challenges in America
“The Ripple Effect” study from On Our Sleeves found that the mental health of their children remains a concern for the large majority of working parents, with almost half of all parents reporting that in the past year their child's mental health has been somewhat or extremely disruptive to their ability to work on most days.
Oct 26, 2022
Saliva, Genomic Analysis Used to Identify Promising Biomarkers for Persistent Post-Concussive Symptoms in Children
In a study published in Frontiers in Public Health, researchers with the Center for Injury Research and Policy, Division of Sports Medicine, and the Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children’s Hospital have demonstrated a method by which increased risk of persistent post-concussive symptoms (PPCS) in children with concussion can be identified. This could allow families and their care teams to better assess recovery time of children with concussion.
Aug 29, 2022
New Study Finds Battery-Related Injuries in Children More than Doubled in Recent Decade
Pediatric battery-related emergency department (ED) visits have increased considerably in the last decade, particularly among children 5 years old and under, according to a new study published today in Pediatrics by a team of researchers from Safe Kids Worldwide and Nationwide Children’s Hospital.
Aug 18, 2022
New Disorder of Copper Metabolism Identified, Caused by Variants in CTR1 Gene
Copper is essential for many cellular functions, including cellular respiration, antioxidant defense, neurotransmitter biosynthesis and neuropeptide amidation, among others. Until recently, only two inborn errors of copper metabolism were well established. Both are rare. Wilson's disease and Menkes disease result from mutations in the copper-transporting P-type ATPases; ATP7B and ATP7A, respectively.
Aug 09, 2022
New Center at Nationwide Children's Hospital Receives Significant NIH Funding
Researchers at Nationwide Children's Hospital recently received coveted P50 Center grant funding from the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), to support a new center focused on suicide prevention.
Jul 27, 2022
St. Baldrick's Foundation Funds $8.9 Million in Grants to Support the Most Promising Childhood Cancer Research
No hospital has a monopoly on good ideas. This is why the St. Baldrick's Foundation funds the most promising research — no matter where it takes place – from your backyard institution to other cutting edge research facilities treating childhood cancers around the globe. Since 2005, this philosophy has translated to more than 1,674 grants in 31 countries, totaling more than $322 million. Thanks to the tremendous efforts of volunteers, donors, partners and advocates across the country this past year, St. Baldrick's is proud to announce $8.9 million has been awarded in new grants.
Mar 23, 2022
Nationwide Children’s Hospital Selected as Clinical Coordinating Center in Large National Clinical Trial Sponsored by National Heart Lung and Blood Institute (NHLBI)
The National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has announced that Nationwide Children’s Hospital has been selected for funding as the Clinical Coordinating Center for the multicenter randomized trial: “Percutaneous intervention versus observational trial of arterial ductus in lower gestational age infants (PIVOTAL)”.
Mar 09, 2022
Early Phase Gene Therapy Study for SMARD1/CMT2S Disease Now Enrolling
Nationwide Children's Hospital has launched a new Phase I/IIa gene replacement clinical study to evaluate the safety of a gene therapy for IGHMBP2-related diseases, specifically spinal muscular atrophy with respiratory distress type 1 (SMARD1) and Charcot Marie Tooth disease type 2S (CMT2S). SMARD1 and CMT2S are rare inherited conditions that are both caused by mutations in the IGHMBP2 gene, of which more than 60 have been found to date. SMARD1 is the most severe form of these diseases and causes muscle weakness and respiratory failure in infancy.
Feb 25, 2022
Dennis Durbin, MD, MSCE, Named President of the Abigail Wexner Research Institute at Nationwide Children’s Hospital
Beginning March 1, 2022, Dennis Durbin, MD, MSCE, will become the third president of the Abigail Wexner Research Institute at Nationwide Children's Hospital. Dr. Durbin joined Nationwide Children's in 2018 as its first chief scientific officer.